Showing results (501-510 of 650) with videos related to
Sort By:
Pageof 65
Nature Cancer|October 31, 2024
Global loss of promoter-enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesisYizhou Zhu, Hayan Lee, Shannon White, et al.Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.Nature Cancer|October 3, 2025
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemiaCarl Sandén, Niklas Landberg, Pablo Peña-Martínez, et al.Nature Cancer|September 25, 2025
SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residenceKaloyan M Tsanov, Francisco M Barriga, Yu-Jui Ho, et al.Nature Cancer|November 22, 2022
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysisLiqin Wang, Haojie Jin, Fleur Jochems, et al.Nature Cancer|July 30, 2021
Future directions in preclinical and translational cancer neuroscience researchIhsan Ekin Demir, Carmen Mota Reyes, Wasfi Alrawashdeh, et al.Nature Cancer|November 21, 2022
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effectYoko Nishiga, Alexandros P Drainas, Maya Baron, et al.Nature Cancer|November 21, 2022
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cellsChristopher J Halbrook, Galloway Thurston, Seth Boyer, et al.Nature Cancer|July 5, 2022
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancerLaura M Spring, Hyo Han, Minetta C Liu, et al.Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.Pageof 65